title: Effects of Propofol on the Liver Oxidative-Antioxidant Balance in a Rat Model of Parkinson's Disease.
abstract: BACKGROUND
  Parkinson's disease is caused by the destruction of dopaminergic neurons in the substantia nigra of the midbrain. One of the possible factors involved in the pathogenesis of Parkinson's disease is impaired oxidativeantioxidative balance.
  
  
  OBJECTIVE
  The present study aimed to evaluate selected parameters of the liver oxidative-antioxidative system in a Wistar rat model with Parkinson's disease treated with propofol.
  
  
  METHODS
  Experiments were performed on 32 rats divided into 4 groups: 1 - control, 2 - Parkinson's disease, 3 - control with propofol, 4 - Parkinson's disease with propofol. The rats were decapitated at 8 weeks of age and their livers were collected. In the liver, the activities of catalase (CAT), glutathione peroxidase (GPx), glutathione transferase (GST), glutathione reductase (GR) and the concentrations of: Malondialdehyde (MDA), total antioxidant capacity (TAC), total oxidant status (TOS) were assessed.
  
  
  RESULTS
  The study demonstrated a decrease in CAT activity and an increase in MDA, TOS concentrations in group 2 compared to that of group 1. Administration of propofol in rats of group 4 caused an increase in CAT activity and a decrease in MDA concentration compared to that of group 2 and an increase in TAC, CAT, GR levels, decrease in MDA levels compared to that of group 1. There was also an increase in GR and TAC in group 3 compared to that of group 1.
  
  
  CONCLUSIONS
  Propofol in Parkinson's disease stimulates the production of antioxidant enzymes in the liver, simultaneously decreasing oxidative stress, which has a beneficial effect on the oxidative-antioxidative balance.
authors.affiliation: Department of Biochemistry, Medical University of Silesia, Zabrze, Poland.
authors.forename: Ewa B
authors.initials: EB
authors.lastname: Romuk
authors.affiliation: Department of Biochemistry, Medical University of Silesia, Zabrze, Poland.
authors.forename: Wioletta
authors.initials: W
authors.lastname: Szczurek
authors.affiliation: Department of Toxicology and Addiction, Medical University of Silesia, Zabrze, Poland.
authors.forename: Przemysław G
authors.initials: PG
authors.lastname: Nowak
authors.affiliation: Department of Biochemistry, Medical University of Silesia, Zabrze, Poland.
authors.forename: Edyta
authors.initials: E
authors.lastname: Hudziec
authors.affiliation: Department of Biochemistry, Medical University of Silesia, Zabrze, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Chwalińska
authors.affiliation: Department of Biochemistry, Medical University of Silesia, Zabrze, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Birkner
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000378:metabolism*; D004195:Disease Models, Animal; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D010084:Oxidation-Reduction / Q000187:drug effects; D010300:Parkinson Disease / Q000378:metabolism*; D015742:Propofol / Q000494:pharmacology*; D017208:Rats, Wistar
chemical_list: D000975:Antioxidants; D015742:Propofol
keywords: Parkinson’s disease; antioxidant effects; oxidative stress; propofol; rats